ExpreS2ion

About:

We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.

Website: http://expres2ionbio.com/

Twitter/X: expres2ionb

Top Investors: Innovation Fund Denmark, Horizon Europe, Horizon 2020

Description:

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Total Funding Amount:

$59.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hørsholm, Hovedstaden, Denmark

Founded Date:

2010-01-01

Contact Email:

info(AT)expres2ionbio.com

Founders:

Charlotte Dyring, Martin Roland Jensen, Wian De Jongh

Number of Employees:

11-50

Last Funding Date:

2024-05-02

IPO Status:

Public

Industries:

© 2025 bioDAO.ai